Navigation Links
Ebola Treatment Shows Promise

Researchers publishing in the most recent issue of The Lancet believe they’re on the track to a possible treatment for the deadly Ebola virus.//

In a study conducted in rhesus monkeys, researchers found injections of a factor known to inhibit blood coagulation called rNAPc2 led to increased survival rates.

The Ebola virus kills its victims by causing severe hemorrhagic fever. This leads to excessive coagulation of the blood and, ultimately, organ failure. In outbreaks in Zaire, about 80 percent of people who contracted the virus died. The death rate in monkey models of the disease has been nearly 100 percent. These researchers wondered if the disease could be stopped by using rNAPc2 to inhibit the blood coagulation pathway.

Researchers from the United States Army Medical Research Institute of Infectious Diseases tested the treatment in nine monkeys who were intentionally infected with the virus. Three additional monkeys were infected with the virus but received no treatment and served as controls. Results show the treatment prolonged survival time. What’s more, 33 percent of the treated monkeys actually survived the disease and regained their health. Just one of the monkeys in the control group survived until the end of the study, and that monkey subsequently died.

The authors write, “Our results have great clinical implications, since our treatment approach of Ebola hemorrhagic fever targets the disease process rather than replication of the infectious agent.” Noting rNAPc2 has a good safety profile in humans, they believe it might also have a role to play in other viral hemorrhagic fevers. “The clinical efficacy of this treatment modality now needs to be proven,” they conclude.

'"/>




Page: 1

Related medicine news :

1. Ebola Virus - Outbreak Claims More Lives In Uganda.
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. Ebola-like virus is on the way to cause epidemic in Angola
4. Fruit Bats Act As Carriers of Ebola Virus
5. Antisense gene specific therapy for Ebola virus
6. Ebola-Outbreak Kills 5000 Gorillas
7. Research on Vaccine Against Ebola Virus
8. Advances in Treatment of Cataracts
9. Recommendations for Treatment of Blood Pressue
10. Treatment for Menieres disease
11. Treatment for pre-menstrual syndrome is ineffective
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the ... in an average life. This mouse sets out on a journey that will show ... Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Psalms of Humidity”: is ... of mind and move the readers one step closer to God. “Psalms of Humidity” ... that his mistakes that have been made within his life are the very same ...
(Date:9/20/2017)... ... ... Sang At Her Funeral”: a tale of murder that will bring a church together ... Sang At Her Funeral” is the creation of published author, Annalise Harold, an IT ... twelve grandchildren. Before becoming a writer, Annalise had the opportunity to relocate often while ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians were ... Brevard’s own Ross A. Clevens, MD, FACS . The founder and medical director ... and Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. He ...
(Date:9/19/2017)... ... 19, 2017 , ... Trusted debt-reduction firm CreditAssociates, LLC has announced two important ... excess of $835 million in resolved debt for its clients. , Credit card debt, ... the categories of debt settled by the company. With more than a decade of ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ... the development of oral drug delivery systems, announced today ... U.S. Food and Drug Administration (FDA) regarding ORMD-0801, the ... At the meeting, the FDA gave clear ... would be a Biologics License Application (BLA).  Such a ...
(Date:8/29/2017)... 2017 ivWatch, LLC, the leading provider of continuous monitoring ... has been awarded an Innovative Technology contract from Vizient, Inc., the ... ... in the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ...
Breaking Medicine Technology: